TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 34890827

Group type: EXPERIMENTAL
Intervention: Peanut Oral Immunotherapy (POIT) with a daily maintenance dose of 3900 mg
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Peanut Oral Immunotherapy (POIT) during maintenance
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Peanut Oral Immunotherapy (POIT) after 1 month of treatment discontinuation
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Peanut Oral Immunotherapy (POIT) after 12 months
Number of subjects: 12
Study: 34639642

Group type: EXPERIMENTAL
Intervention: Personal Health Record (PHR) intervention
Number of subjects: 7350

Group type: COMPARATOR
Intervention: Control group (no PHR)
Number of subjects: 7350
Study: 32459070

Group type: EXPERIMENTAL
Intervention: Tac withdrawal
Number of subjects: 14

Group type: COMPARATOR
Intervention: Tac maintenance
Number of subjects: 14
Study: 33159422

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 146

Group type: COMPARATOR
Intervention: Relaxation control (progressive muscle relaxation)
Number of subjects: 146
Study: 35481712

Group type: EXPERIMENTAL
Intervention: rosuvastatin 10 mg daily for 3 months
Number of subjects: 228

Group type: COMPARATOR
Intervention: conventional treatment (warfarin or rivaroxaban)
Number of subjects: 228
Study: 35130214

Group type: EXPERIMENTAL
Intervention: 1% clotrimazole ear drops
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 3% salicylic acid drops
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: 10% povidone iodine drops
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Overall response to treatment
Number of subjects: 120
Study: 35091463

Group type: EXPERIMENTAL
Intervention: Biologic therapy
Number of subjects: 203

Group type: COMPARATOR
Intervention: Not applicable (control group)
Number of subjects: 203
Study: 32807659

Group type: EXPERIMENTAL
Intervention: Silver barrel contact lens storage cases
Number of subjects: 48

Group type: COMPARATOR
Intervention: Non-silver (control) barrel contact lens storage cases
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Hydrogel lenses in combination with silver cases
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Compliance score
Number of subjects: 48
Study: 35709245

Group type: EXPERIMENTAL
Intervention: Abbreviated Progressive Muscle Relaxation (APMR)
Number of subjects: 114

Group type: EXPERIMENTAL
Intervention: Mindful Breathing (MB)
Number of subjects: 114

Group type: COMPARATOR
Intervention: Self-Monitoring (SM)
Number of subjects: 114
Study: 32627420

Group type: EXPERIMENTAL
Intervention: ABP 798
Number of subjects: 0

Group type: COMPARATOR
Intervention: Rituximab RP (US and EU sourced)
Number of subjects: 0
Study: 36216624

Group type: EXPERIMENTAL
Intervention: Extraction treatment (4 first premolars removed)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Nonextraction treatment
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Extraction treatment with minimal lip strain
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Extraction treatment
Number of subjects: 60
Study: 35662502

Group type: EXPERIMENTAL
Intervention: Autologous dendritic‐cell vaccine therapy combined with systemic therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Everolimus
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 32631388

Group type: EXPERIMENTAL
Intervention: AHE (Allium hookeri extract) 486 mg/day
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 36318499

Group type: EXPERIMENTAL
Intervention: Narrative writing intervention with resources and support from a narrative medicine facilitator
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative thematic analysis of written texts
Number of subjects: 0
Study: 34731574

Group type: EXPERIMENTAL
Intervention: Conversation group treatment (1 hr, twice per week, for 10 weeks)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 48

Group type: COMPARATOR
Intervention: Treated groups and Control group
Number of subjects: 48
Study: 32888150

Group type: EXPERIMENTAL
Intervention: Irrigation with wastewater (source not specified)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Irrigation with varied water sources (three sources)
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Bioaccumulation, translocation, bio-concentration, daily intake, and enrichment values of cadmium
Number of subjects: 5
Study: 33878429

Group type: EXPERIMENTAL
Intervention: tDCS applied at high vigilance
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: tDCS applied at low vigilance
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: tDCS applied at a random moment
Number of subjects: 16
Study: 32147071

Group type: EXPERIMENTAL
Intervention: Topical henna preparation applied every night for two weeks
Number of subjects: 95

Group type: COMPARATOR
Intervention: Topical placebo
Number of subjects: 95
Study: 36315457

Group type: EXPERIMENTAL
Intervention: Medical-grade honey (MGH) applied intra-socket (L-Mesitran Soft)
Number of subjects: 21

Group type: COMPARATOR
Intervention: Control (no treatment applied)
Number of subjects: 21
Study: 33494622

Group type: EXPERIMENTAL
Intervention: FS-LASIK
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: SMILE
Number of subjects: 165
Study: 32501985

Group type: COMPARATOR
Intervention: High-dose tirofiban (20 μg/kg)
Number of subjects: 312

Group type: COMPARATOR
Intervention: Medium-dose tirofiban (10 μg/kg)
Number of subjects: 312
Study: 35389229

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 35886120

Group type: EXPERIMENTAL
Intervention: Quit with US smartphone application
Number of subjects: 273

Group type: COMPARATOR
Intervention: Control group (pharmacists’ smoking cessation counseling only)
Number of subjects: 273
Study: 33116073

Group type: EXPERIMENTAL
Intervention: Scapula training exercises
Number of subjects: 46

Group type: COMPARATOR
Intervention: Conventional therapeutic exercise and physical therapy
Number of subjects: 46
Study: 36006034

Group type: EXPERIMENTAL
Intervention: Gabapentin (100 mg)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo (100 mg lactose powder)
Number of subjects: 10
Study: 33160854

Group type: EXPERIMENTAL
Intervention: Tα1 treatment (1.6 mg subcutaneous injection for 15 days)
Number of subjects: 127

Group type: COMPARATOR
Intervention: Control group (untreated, regular supportive treatment)
Number of subjects: 127
Study: 32898435

Group type: EXPERIMENTAL
Intervention: 20 W/LSI 4
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 20 W/LSI 5
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 40 W/LSI 4
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: 40 W/LSI 5
Number of subjects: 80
Study: 35961801

Group type: EXPERIMENTAL
Intervention: Health Education (HE) + Progressive Muscle Relaxation (PMR)
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Progressive Muscle Relaxation (PMR)
Number of subjects: 108

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 108
Study: 32993359

Group type: EXPERIMENTAL
Intervention: Court-type Thai traditional massage
Number of subjects: 40

Group type: COMPARATOR
Intervention: Senokot treatment
Number of subjects: 40
Study: 33089621

Group type: EXPERIMENTAL
Intervention: BaSO4 ‐ and Bi2 O3 ‐containing White MTA Angelus
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: ProRoot MTA
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Bi2 O3 ‐containing white Portland cement
Number of subjects: 36

Group type: COMPARATOR
Intervention: Negative control (lateral wall of the tubes)
Number of subjects: 36
Study: 35688662

Group type: EXPERIMENTAL
Intervention: Capivasertib plus docetaxel
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo plus docetaxel
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Capivasertib plus docetaxel (in patients previously treated with abiraterone and/or enzalutamide)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo plus docetaxel (in patients previously treated with abiraterone and/or enzalutamide)
Number of subjects: 150

Group type: EXPERIMENTAL
Intervention: Capivasertib plus docetaxel (in abiraterone/enzalutamide-naïve patients)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Placebo plus docetaxel (in abiraterone/enzalutamide-naïve patients)
Number of subjects: 150
Study: 33706002

Group type: EXPERIMENTAL
Intervention: Fitline-Coaching (eight weekly nutritionist-delivered coaching calls with workbook)
Number of subjects: 494

Group type: COMPARATOR
Intervention: Fitline-Workbook (same workbook in eight mailings without coaching)
Number of subjects: 494
Study: 32072071

Group type: EXPERIMENTAL
Intervention: Spironolactone 100 mg
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Spironolactone 200 mg
Number of subjects: 90

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 90
Study: 35022730

Group type: EXPERIMENTAL
Intervention: Ceftolozane/tazobactam (3 g, 2 g ceftolozane/1 g tazobactam q8h)
Number of subjects: 511

Group type: COMPARATOR
Intervention: Meropenem (1 g q8h)
Number of subjects: 511
Study: 33407763

Group type: EXPERIMENTAL
Intervention: Volatile anesthetics during cardiopulmonary bypass
Number of subjects: 100
Study: 35231769

Group type: EXPERIMENTAL
Intervention: 0.5 g/kg EO-PGS
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 0.75 g/kg EO-PGS
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: 1.0 g/kg EO-PGS
Number of subjects: 480

Group type: EXPERIMENTAL
Intervention: EO-PGS groups
Number of subjects: 480
Study: 34874420

Group type: EXPERIMENTAL
Intervention: Mediterranean diet (n=407)
Number of subjects: 1221

Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (n=407)
Number of subjects: 1221

Group type: COMPARATOR
Intervention: Usual care (n=407)
Number of subjects: 1221
Study: 35904640

Group type: EXPERIMENTAL
Intervention: Throat packs (TP)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Throat packs (TP) placed by anesthesiologist (B2)
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Throat packs (TP) placed by surgeon (B1)
Number of subjects: 148

Group type: COMPARATOR
Intervention: No throat packs (Control group A)
Number of subjects: 148
Study: 34194240

Group type: EXPERIMENTAL
Intervention: Quercetin Phytosome® (QP)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Standard of Care (SC)
Number of subjects: 42
Study: 32592736

Group type: EXPERIMENTAL
Intervention: Home-based palliative care
Number of subjects: 1357
Study: 35254752

Group type: EXPERIMENTAL
Intervention: Oral tranexamic acid (TXA) with fluocinolone-based triple cream
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fluocinolone-based triple cream alone
Number of subjects: 0
Study: 34544117

Group type: EXPERIMENTAL
Intervention: Fastball EEG method for recognition memory assessment
Number of subjects: 60

Group type: COMPARATOR
Intervention: Behavioural 2AFC task
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fastball EEG method
Number of subjects: 60
Study: 34106556

Group type: EXPERIMENTAL
Intervention: Fetoscopic endoluminal tracheal occlusion (FETO)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Expectant care
Number of subjects: 80
Study: 615918511

Group type: EXPERIMENTAL
Intervention: Action game training (first person shooter) for 10 hours
Number of subjects: 40

Group type: COMPARATOR
Intervention: Computer-based card game (control group) for 10 hours
Number of subjects: 40
Study: 34806244

Group type: EXPERIMENTAL
Intervention: Methamphetamine use only
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Methamphetamine and crack-cocaine use
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: Party and play use (methamphetamine, gamma-hydroxybutyrate, amyl nitrites, erectile dysfunction drugs)
Number of subjects: 161

Group type: EXPERIMENTAL
Intervention: High polysubstance use
Number of subjects: 161

Group type: COMPARATOR
Intervention: Demographic and psychological factors
Number of subjects: 161
Study: 33148766

Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 64
Study: 34174212

Group type: EXPERIMENTAL
Intervention: Children's liquid soap with pH 5.8 (experimental group)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Common liquid soap with pH 7.0 (control group)
Number of subjects: 204

Group type: COMPARATOR
Intervention: Both groups (no soap used on forehead)
Number of subjects: 204
Study: 32419092

Group type: EXPERIMENTAL
Intervention: Manual bolus-tracking (MBT, n=25)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Fixed delay time (FDT, n=25)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Automatic bolus-tracking (ABT, n=25)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Total effective dose (FDT)
Number of subjects: 75

Group type: COMPARATOR
Intervention: Total effective dose (ABT)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Total effective dose (MBT)
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Comparison of total effective doses among groups A, B, and C
Number of subjects: 75
Study: 36397128

Group type: EXPERIMENTAL
Intervention: Empagliflozin (10 mg/daily)
Number of subjects: 95
Study: 32067401

Group type: EXPERIMENTAL
Intervention: Oral Appliance (OA)
Number of subjects: 17

Group type: COMPARATOR
Intervention: No Oral Appliance (no OA)
Number of subjects: 17
Study: 36695874

Group type: COMPARATOR
Intervention: Common standard arm 3 + 7 (CSA)
Number of subjects: 1286

Group type: EXPERIMENTAL
Intervention: Study group A (TAD/HAM versus HAM/HAM ± G‐CSF followed by TAD and maintenance)
Number of subjects: 1286

Group type: EXPERIMENTAL
Intervention: Study group B (intermediate‐dose ara‐C/mitoxantrone followed by ara‐C/mitoxantrone)
Number of subjects: 1286
Study: 33611761

Group type: EXPERIMENTAL
Intervention: High-dose methotrexate-based chemotherapy with rituximab
Number of subjects: 0

Group type: COMPARATOR
Intervention: High-dose methotrexate-based chemotherapy without rituximab
Number of subjects: 0
Study: 35044471

Group type: EXPERIMENTAL
Intervention: Prolonged Exposure (PE) therapy
Number of subjects: 916

Group type: COMPARATOR
Intervention: Cognitive Processing Therapy (CPT)
Number of subjects: 916
Study: 35010917

Group type: EXPERIMENTAL
Intervention: CIT plus BR (3 g/kg/day of CIT plus 3 mg/kg/day of nitrates)
Number of subjects: 32

Group type: COMPARATOR
Intervention: CIT (3 g/kg/day)
Number of subjects: 32

Group type: COMPARATOR
Intervention: BR (3 mg/kg/day of NO3‐)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Placebo (PLG)
Number of subjects: 32
Study: 36434542

Group type: EXPERIMENTAL
Intervention: Hydrolysed meat puree
Number of subjects: 22

Group type: COMPARATOR
Intervention: Control diet (unaltered freshly made pureed diets)
Number of subjects: 22
Study: 34886337

Group type: EXPERIMENTAL
Intervention: High-Intensity Interval Training (HIIT) for 6 weeks, performed thrice weekly (12‐16‐20 × 30‐s intervals interspersed with 1‐min rest periods)
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (no training)
Number of subjects: 19
Study: 36045183

Group type: EXPERIMENTAL
Intervention: Photobiomodulation therapy using an 830-nm LED device
Number of subjects: 43

Group type: COMPARATOR
Intervention: Sham device without an LED
Number of subjects: 43
Study: 35152127

Group type: EXPERIMENTAL
Intervention: Ketamine with Haloperidol
Number of subjects: 200

Group type: COMPARATOR
Intervention: Fentanyl
Number of subjects: 200
Study: 34917633

Group type: EXPERIMENTAL
Intervention: Intravenous methylprednisolone (MP) 0.5 mg/kg, two times daily for 5 days
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 118
Study: 35285397

Group type: EXPERIMENTAL
Intervention: Conventional hydrotherapy combined with aquatic lower extremity strength training
Number of subjects: 56

Group type: COMPARATOR
Intervention: Conventional hydrotherapy
Number of subjects: 56
Study: 33468518

Group type: EXPERIMENTAL
Intervention: Digital intervention for self-monitoring of blood pressure (305 participants)
Number of subjects: 622

Group type: COMPARATOR
Intervention: Usual care (317 participants)
Number of subjects: 622
Study: 36369323

Group type: EXPERIMENTAL
Intervention: Whole-body Photobiomodulation (PBM)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo PBM
Number of subjects: 42
Study: 33588594

Group type: EXPERIMENTAL
Intervention: Dabigatran (150 or 110 mg BID)
Number of subjects: 988

Group type: COMPARATOR
Intervention: Aspirin (100 mg QD)
Number of subjects: 988
Study: 36323305

Group type: EXPERIMENTAL
Intervention: Virtual reality simulator
Number of subjects: 20
Study: 33017580

Group type: EXPERIMENTAL
Intervention: Ultra-low-dose quadruple combination therapy (quadpill) containing irbesartan 37.5 mg, amlodipine 1.25 mg, indapamide 0.625 mg, and bisoprolol 2.5 mg
Number of subjects: 650

Group type: COMPARATOR
Intervention: Control therapy of a single identical-appearing pill containing irbesartan 150 mg
Number of subjects: 650

Group type: EXPERIMENTAL
Intervention: Both arms will provide step-up therapy of open-label amlodipine 5 mg if blood pressure is >140/90 at 6 weeks
Number of subjects: 650
Study: 35120864

Group type: EXPERIMENTAL
Intervention: TEAM intervention (6 visits with pharmacist-technician team)
Number of subjects: 576

Group type: EXPERIMENTAL
Intervention: TEAM intervention
Number of subjects: 576

Group type: COMPARATOR
Intervention: Control (printed information only)
Number of subjects: 576
Study: 35142630

Group type: EXPERIMENTAL
Intervention: app+classes
Number of subjects: 211

Group type: EXPERIMENTAL
Intervention: app‐only
Number of subjects: 211

Group type: COMPARATOR
Intervention: WLC
Number of subjects: 211
Study: 33638647

Group type: EXPERIMENTAL
Intervention: non-faith-based abstinence-only
Number of subjects: 613

Group type: EXPERIMENTAL
Intervention: faith-based abstinence-only
Number of subjects: 613

Group type: COMPARATOR
Intervention: attention-matched health-promotion control
Number of subjects: 613
Study: 32374030

Group type: EXPERIMENTAL
Intervention: FDC-2 (10 mg macitentan/40 mg tadalafil)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-component tablets of macitentan (10 mg) and tadalafil (40 mg)
Number of subjects: 0
Study: 35093678

Group type: EXPERIMENTAL
Intervention: Donepezil (N=797)
Number of subjects: 1554

Group type: COMPARATOR
Intervention: Placebo (N=484)
Number of subjects: 1554
Study: 34620151

Group type: EXPERIMENTAL
Intervention: Kami-guibi-tang (KGT)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study: 35566643

Group type: COMPARATOR
Intervention: Connettivina® Bio Plus (Group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Fitostimoline® Plus (Group B)
Number of subjects: 60
Study: 35511451

Group type: EXPERIMENTAL
Intervention: Pressure-controlled ventilation-volume guaranteed (PCV-VG) with tidal volume set to 6 ml/kg and PEEP at 7 cm H2O
Number of subjects: 0

Group type: COMPARATOR
Intervention: Volume controlled ventilation (VCV) with tidal volume set to 8 ml/kg
Number of subjects: 0
Study: 35487026

Group type: EXPERIMENTAL
Intervention: Anodal tDCS
Number of subjects: 20

Group type: COMPARATOR
Intervention: Sham tDCS
Number of subjects: 20
Study: 33749377

Group type: EXPERIMENTAL
Intervention: Higher genetically predicted childhood BMI
Number of subjects: 14802

Group type: EXPERIMENTAL
Intervention: Adult BMI
Number of subjects: 14802

Group type: COMPARATOR
Intervention: Adjusted for adult BMI
Number of subjects: 14802
Study: 32635933

Group type: EXPERIMENTAL
Intervention: PROMISE protocol (adapted V-MIS protocol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control condition (standard V-MIS protocol)
Number of subjects: 0
Study: 35224774

Group type: EXPERIMENTAL
Intervention: Screw-retained (SR) all-ceramic single crown
Number of subjects: 44

Group type: COMPARATOR
Intervention: Cemented (CR) all-ceramic single crown
Number of subjects: 44
Study: 33231037

Group type: EXPERIMENTAL
Intervention: Sensitivity to pathogen disgust
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Purity concerns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Harm-related moral concerns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Pathogen disgust
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Sexual and injury disgust
Number of subjects: 0
Study: 35361440

Group type: EXPERIMENTAL
Intervention: Omega-3 supplements
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 34117342

Group type: EXPERIMENTAL
Intervention: Usual care plus home‐based foot‐ankle exercises
Number of subjects: 20

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 20
Study: 35674122

Group type: EXPERIMENTAL
Intervention: Self-Help Plus (SH +)
Number of subjects: 459

Group type: COMPARATOR
Intervention: Enhanced treatment as usual (ETAU)
Number of subjects: 459
Study: 35138550

Group type: EXPERIMENTAL
Intervention: Patient-Centred Sleep Study Report (PCSR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard Care
Number of subjects: 0
Study: 34099065

Group type: EXPERIMENTAL
Intervention: BIA-directed fluid resuscitation
Number of subjects: 140

Group type: COMPARATOR
Intervention: Traditional fluid resuscitation (TRD)
Number of subjects: 140
Study: 32289160

Group type: EXPERIMENTAL
Intervention: Blinatumomab maintenance therapy (cycles ≥6)
Number of subjects: 267

Group type: COMPARATOR
Intervention: Blinatumomab induction therapy
Number of subjects: 267
Study: 36250938

Group type: EXPERIMENTAL
Intervention: Intravesical mitomycin-C (IMMC) 40 mg/20 mL, administered 1 day and 4 hours before TURBT
Number of subjects: 99

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Intravesical mitomycin-C (IMMC)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 99
Study: 34261530

Group type: EXPERIMENTAL
Intervention: Intradermal acupuncture (IA) treatment
Number of subjects: 132

Group type: COMPARATOR
Intervention: Sham intradermal acupuncture (sham IA) treatment
Number of subjects: 132
Study: 35773113

Group type: EXPERIMENTAL
Intervention: Extended-release naltrexone
Number of subjects: 474

Group type: COMPARATOR
Intervention: Buprenorphine
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Sedative use (pretreatment)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Cocaine use (initial 4 weeks of treatment)
Number of subjects: 474

Group type: EXPERIMENTAL
Intervention: Sedative use (initial 4 weeks of treatment)
Number of subjects: 474
Study: 34518469

Group type: EXPERIMENTAL
Intervention: Montelukast
Number of subjects: 113

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 113
Study: 34144282

Group type: EXPERIMENTAL
Intervention: 0.5 g EP/calf per day (ECL)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: 5 g EP/calf per day (ECH)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study: 33824584

Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 13885

Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 13885